AlphAIAlphAI — Financial news for AI agents
globes.co.ilSEP 92 min read$TEVA

After credit upgrade, Teva plans to recycle debt

Teva Pharmaceutical (NYSE: TEVA) received investment-grade debt ratings from all three major agencies. It plans to issue new bonds to repay existing higher-interest debt, totaling $1.25B, $398M, and up to $450M in USD, plus up to €1.25B in euros. The move aims to reduce interest costs and improve financial flexibility, following a strategy to return to growth. Teva's debt stood at $16.6B at Q2's end, with 27% short-term. The company will also switch to trading ordinary shares on NYSE instead of

Original reporting
globes.co.il
Published Sep 9, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
After credit upgrade, Teva plans to recycle debt — source image
Source · globes.co.il
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The upgrade and debt‑recycling plan improve financial flexibility and may lift the equity price.

02

Market read

First report of Teva's credit upgrade and senior note issuance, a material corporate action for traders.

03

What to watch

Potential dilution of existing bondholders and the impact of upcoming NYSE listing change.

Relevance 7/10Novelty 7/10Timing: today

Background

Teva, a global pharmaceutical company, recently received investment‑grade ratings from S&P, Fitch, and Moody's.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva announced a credit rating upgrade to BBB- and a plan to issue senior notes to recycle $1.25B of 2028 bonds and other series.

Expected impact

Potential modest upside as investors price in lower financing costs.

Evidence & confidence

Improved credit rating and active debt reduction are favorable fundamentals for a large pharma.

Market effects

Sector

May encourage other pharma issuers to consider debt refinancing after rating upgrades.

Regional

Positive for Israeli market sentiment as a major exporter improves credit profile.

Global

Limited to fixed‑income and pharma equity investors.

Counterpoint

What could challenge this read

If the new notes are priced at a premium, the net benefit could be muted.

Key entities

  • Executive
    Eli Kalif

    Chief Financial Officer of Teva who commented on the rating upgrades.

  • Executive
    Richard Francis

    CEO of Teva overseeing the NYSE listing transition.

Read at source← All news

Related articles

SEP 10
$TEVAMedAI 9/10

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Teva Pharmaceutical Industries Ltd. (TEVA) announced the successful pricing of approximately $4.9 billion in senior notes. The proceeds will fund redemptions of certain existing notes, pay related fees, and be used for general corporate purposes, including debt repayment. The notes are expected to settle on or about September 16, 2026, subject to customary closing conditions.

montrealgazette.com2 min
SEP 7
$ALCLow

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

tradingview.com3 min
SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min